According to the EMAs Pharmacovigilance Risk Assessment Committee, NAION will be listed as a rare side effect, meaning it may occur in up to 1 in 10,000 patients after a year or more of treatment
Taken together, the findings suggest that regular re-vaccination with updated COVID-19 vaccines against variants might give people the tools to fight off not only the SARS-CoV-2 variants represented in the vaccines, but also other SARS-CoV-2 variants and related coronaviruses, possibly including ones that have not yet emerged
Other side effects include diarrhoea (up to 30% on semaglutide and 20% on tirzepatide), vomiting (25% vs 12% respectively), constant sinusistis/pharyngitis (up to 20%), headaches (15% vs 6%), abdominal pain (10% vs 5%)
PMID 18856156
Without that change-control language, a buyer may approve one source and receive another risk profile later